Latest information on COVID-19
Support teaching, research, and patient care.
Dr. Goel is a general and transplant hepatologist who specializes in caring for patients with chronic liver disease, viral hepatitis, fatty liver, autoimmune disorders, hepatocellular cancer and cirrhosis. She cares for patients before and after liver transplantation. Dr. Goel incorporates the most recent, evidence-based medicine in her practice and is passionate about ensuring the safest and highest quality of care for her patients. She engages her patients and their families in understanding the disease and in creating a comprehensive treatment plan. She is committed to teaching the next generation of hepatologists to do the same. She has a particular clinical interest in the management of patients with autoimmune liver disease including autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis and sarcoidosis. She is the leading institutional principal investigator for several clinical trials for these rare autoimmune liver conditions. Dr. Goel is also involved in several national and international collaborations to further our research and treatment of autoimmune hepatitis, PBC and PSC.
Dr. Goel is interested in studying the complications and management of patients with end-stage liver disease, including infections, bleeding and encephalopathy. As the waitlist for liver transplantation continues to grow, many patients develop consequences of decompensated liver disease. It is becoming increasingly important to improve our understanding and care of these complications in order to optimize the quality of life for this growing population of patients.She is also particularly interested in the management of patients with autoimmune liver disease including autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis among others.
RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
To evaluate the treatment effect of seladelpar on composite biochemical improvement in
cholestasis markers based on ALP and total bilirubin and to evaluate the safety of seladelpar
over 12 months of treatment compared to placebo
View full details
Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
Primary objective: To evaluate the efficacy of hymecromone plus standard of care compared
with standard of care alone in the treatment of adolescents and adults with primary
sclerosing cholangitis (PSC).
Secondary objectives: To evaluate the change in Alkaline Phosphatase (ALP) from baseline to 6
months post-treatment following treatment with hymecromone plus standard of care compared
with standard of care.
To evaluate changes in biomarkers of PSC disease during hymecromone treatment, namely: (a)
fibrotic effect (FibroScan); (b) inflammatory biomarkers (serum Hyaluronan (HA)); and, (c)
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment
This is a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating
Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic
Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)
A Phase 2a, multicenter, randomized, double-blind, dose-ranging, placebo-controlled, study to
evaluate the safety, tolerability, and PK of PLN-74809 in participants with primary
sclerosing cholangitis and suspected liver fibrosis
Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis
The primary objective of this study is to evaluate whether cilofexor reduces the risk of
fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in
Subjects with Primary Biliary Cholangitis (PBC)
ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy
of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response
to or intolerance to ursodeoxycholic acid (UDCA)
The participants might enter the ongoing open-label safety study (NCT03301506) following this
ALTA TIPS: A 5-year Longitudinal Observational Study of Patients Undergoing TIPS Placement
ALTA is a multicenter consortium focused on the management of portal hypertension. ALTA TIPS
is a longitudinal observational study of patients who are undergoing transjugular
intrahepatic portosystemic shunt (TIPS) placement. ALTA will create a database that will
provide clinical parameters and outcomes of patients undergoing TIPS as part of their
standard of care in hopes of answering key clinical questions.
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
This is a 5-year, longitudinal, observational study of patients with PBC designed to
specifically address important clinical questions that remain incompletely answered from
registration trials. In addition to the study database, a bio specimen repository will also
be included so that translational studies of genomics and biomarkers of response may be
Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT
Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis,
and Coronavirus Disease 2019 with [18F]FP-R01-MG-F2 with PET/CT